Online inquiry

IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2145MR)

This product GTTS-WQ2145MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2145MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12555MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ5655MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ11055MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ9811MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ5606MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ7249MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ12571MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ8901MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IGE25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW